Metropolis Healthcare Reports 13% Surge in Q2 Net Profit, Declares Interim Dividend
Metropolis Healthcare, a leading diagnostic services provider, reported strong Q2 FY2025-26 results. Net profit increased 13% to ₹527.00 million, while revenue grew 22.9% to ₹4.30 billion compared to the same quarter last year. The company declared an interim dividend of ₹4.00 per equity share, with the record date set for November 11, 2025. These results demonstrate Metropolis Healthcare's operational efficiency and strong market position in the diagnostic services sector.

*this image is generated using AI for illustrative purposes only.
Metropolis Healthcare , a leading diagnostic services provider, has reported a robust financial performance for the second quarter of the fiscal year 2025-26, with significant growth in both revenue and profitability.
Financial Highlights
The company's consolidated net profit for Q2 rose to ₹527.00 million, marking a 13% increase from ₹465.00 million in the same quarter last year. This growth in profitability was accompanied by a substantial increase in revenue, which grew to ₹4.30 billion, up from ₹3.50 billion in the corresponding period of the previous year.
| Metric | Q2 FY2025-26 | Q2 FY2024-25 | YoY Growth |
|---|---|---|---|
| Net Profit | ₹527.00 million | ₹465.00 million | 13.00% |
| Revenue | ₹4.30 billion | ₹3.50 billion | 22.90% |
Operational Performance
The significant growth in both revenue and profitability underscores Metropolis Healthcare's strong operational performance and market position in the diagnostic services sector. The company's ability to increase its top line by nearly 23% while improving its bottom line by 13% demonstrates effective cost management and operational efficiency.
Interim Dividend Declaration
In a move that will likely please shareholders, the Board of Directors of Metropolis Healthcare has declared an interim dividend of ₹4.00 per equity share for the financial year 2025-26. The record date for the purpose of this interim dividend payment has been set as November 11, 2025.
Management Commentary
While specific management comments were not provided, the strong financial results suggest that Metropolis Healthcare's strategic initiatives and market positioning are yielding positive outcomes. The company's ability to grow its revenue significantly while also improving profitability indicates a well-executed business strategy in a competitive healthcare diagnostics market.
Looking Ahead
As Metropolis Healthcare continues to demonstrate strong financial performance, investors and industry observers will be watching closely to see if this growth trajectory can be maintained in the coming quarters. The company's ability to capitalize on the growing demand for diagnostic services while managing costs effectively will be crucial for its future success.
Metropolis Healthcare's Q2 results reflect a company on a solid growth path, with improvements across key financial metrics. The declaration of an interim dividend further underscores the company's financial health and its commitment to delivering value to shareholders.
Historical Stock Returns for Metropolis Healthcare
| 1 Day | 5 Days | 1 Month | 6 Months | 1 Year | 5 Years |
|---|---|---|---|---|---|
| +1.31% | +4.46% | -2.04% | +19.43% | -3.48% | +4.91% |









































